Fermenta Biotech Ltd
P&L
Quarterly Consolidated
vs Q2 FY26
Fermenta Biotech's 9MFY26 Revenue Surges 25% YoY, Net Profit Up 20% YOY
09 Feb 2026 · 9 Feb, 4:07 pm
Summary
Fermenta Biotech Limited, a leading manufacturer of pre-premium-grade APIs, intermediates, and mixes of vitamins and minerals for the global markets, announced its consolidated revenue for the nine months ended 31 December 2025 was INR 413.6 crore, up 41% from the same year-ago period. The company's EBITDA for the same period was INR 95.1 crore, up 86% from the same year-ago period.
Key Highlights
- 1
Consolidated Revenue for 9MFY26 INR 421.2 crore, up by INR 83.6 crore YoY
- 2
Consolidated EBITDA for 9MFY26 INR 97.2 crore, up 20% YoY
- 3
Q3FY26 Consolidated Revenues INR 140.5 crore, down 11% YoY; up 4% QoQ
- 4
Revenue mix (consolidated) OMFY26 OMFY25 YoY change (%)
- 5
Human nutrition segment volumes grew 46% over 9MFY25
- 6
Animal nutrition segment volumes grew 52% over 9MFY25 and average realization down by 8% over 9MFY25
- 7
Greenchemistry sales in 9M FY26 surpassed those in full-year FY25
- 8
INR 110 crore capex at Dahej for plant-based Vitamin D3, green chemistry enzymes, and Vitamin D3 derivatives
Management Comments
Prashant Nagre
Managing Director
The turnaround of FY25 was further confirmed in 9MFY26. While growth of revenue, excluding that from real estate unlocking, was 57% in FY25 over FY24, in 9MFY26 revenue was already 96.9% of that achieved in full FY25. Our 9MFY26 EBITDA (excluding real estate) demonstrates robust operational leverage—in just nine months of FY26, we have already surpassed our full-year FY25 EBITDA by 14.1%.
Informational and educational content only. Not investment advice.